Business
Nuwellis Announces $5 Million Private Placement and Warrant Inducement Transaction, Priced At-The-Market
MINNEAPOLIS, Jan. 29, 2026 (GLOBE NEWSWIRE) -- Nuwellis, Inc. (Nasdaq: NUWE) (“Nuwellis” or the “Company”), a medical technology company focused on advancing precision cardiorenal care in critical care settings, today announced that it has entered into a securities purchase agreement with an institutional and accredited investor (the “Investor”) for the purchase and sale of 994,537 shares (the “Shares”) of the Company’s common stock, $0.0001 par value (the “Common Stock”) or (pre-funded warrants
About this update from Nuwellis, Inc.
[{"type":"image","alt":"Nuwellis, Inc.","displaySize":"","headline":null,"caption":"Nuwellis, Inc.","className":"","disableSlideshowImg":false,"size":{"original":{"width":300,"height":72,"url":"https://media.zenfs.com/en/globenewswire.com/d2460037586c5d451999b7d63383d34b"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/epm_zxode7LAVlWVBg62FQ--/YXBwaWQ9aGlnaGxhbmRlcjt3PTQyMDtoPTEwMTtjZj13ZWJw/https://media.zenfs.com/en/globenewswire.com/d2460037586c5d451999b7d63383d34b","width":300,"height":72}},"lazy":false},{"type":"text","content":"MINNEAPOLIS, Jan. 29, 2026 (GLOBE NEWSWIRE) -- Nuwellis, Inc. (Nasdaq: NUWE) (“Nuwellis” or the “Company”), a medical technology company focused on advancing precision cardiorenal care in critical care settings, today announced that it has entered into a securities purchase agreement with an institutional and accredited investor (the “Investor”) for the purchase and sale of 994,537 shares (the “Shares”) of the Company’s common stock, $0.0001 par value (the “Common Stock”) or (pre-funded warrants in-lieu thereof) together with warrants (the “Private Placement Warrants”) to purchase 1,989,074 shares of Common Stock in a private placement priced at-the-market under Nasdaq rules (the “Private Placement”). The combined effective offering price for each Share (or pre-funded warrant in-lieu thereof) and Private Placement Warrant is $3.09. The Private Placement Warrants will have an exercise price of $2.84 per share, will be exercisable immediately upon issuance, and will expire on the five-year anniversary of the date that a resale registration statement related to the Shares and Private Placement Warrants becomes effective.","length":1135,"tagName":"p"},{"type":"text","content":"The Company also announced today that it has entered into a warrant inducement agreement with the Investor for the immediate exercise of certain outstanding warrants that the Company issued on November 6, 2024 and June 10, 2025 (the “Existing Warrants”), in a transaction priced at-the-market under Nasdaq rules (the “Warrant Inducement”). Pursuant to the warrant inducement agreement, the Investor has agreed to a reduced exercise price of the outstanding Existing Warrants to an amended exercise price of $3.09, and to exercise the outstanding Existing Warrants to purchase an aggregate of 623,585 shares of the Company’s common stock. In consideration for t...